…
He is knowledgeable, attentive and receptive to questions anytime.Listen to Dr. Wagner discuss stem cell therapy on KOMO News with Tom and Shannon.Jamie is 60 years old and was facing a total knee replacement. But, he says, one type of stem cell often researched, the induced pluripotent stem cell, was only discovered in 2006.
Over 5 million stem cell procedures for osteoarthritis have been performed in the United States with no significant adverse effects reported. Advisory Board for the Medical Protective Company – May 2013 – current Founder – Cells on Ice, Inc. – SVF and stem cell cryopreservation and laboratories in affiliation with American CryoStem, February 2015. Human stem cells can come from an embryo or an adult human. ... and I like the idea that at the 100-year mark we may … The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and ResearchThe chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.Mark Freedman, MD: An Update on Stem Cell Research in MSThe director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.Ofatumumab Increases NEDA-3 Likelihood in MS Compared With TeriflunomideNovartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.Ocrelizumab Has Similar Effects in MS With Shorter Infusion TimeThe Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.Evobrutinib Shows Long-Term Efficacy and Safety in Phase 2 StudyEvobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.Siponimod Reduces Risk of Disability Progression Regardless of Prior Relapses in MSThe Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.Natalizumab Provides Superior 'Feel Good' Experience in MS Over Other TreatmentsIncreases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.MSProDiscuss Tool Is Usable and Useful in MS Clinical PracticeA real-world survey of more than 300 health care practitioners suggests that the MSProDiscuss tool offers a useful tool for the physician-patient discussion on multiple sclerosis disease progression.Satralizumab Shows Safe Profile in Patients With NMOSDData from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.Pediatric MS Disease Activity May Increase Upon MenarcheFindings from a study of more than 500 girls with multiple sclerosis suggest that first menstruation and the onset of puberty may be a time of increased disease activity in pediatric MS.Levels of GFAP Higher in NMOSD, Suggesting It May Serve as a Biomarker A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.Cladribine Deemed Well-Tolerated in MS Treatment, Could Influence Adherence RatesAn analysis of data from the phase 3 development of cladribine (Mavenclad; EMD Serono) showed that the incidence of treatment-emergent adverse events was low and most were mild in intensity.Aerobic Exercise Shows Positive Effect in Multiple SclerosisImprovements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.Novel BTK Inhibitor Evobrutinib Displays Long-Term Success in MSThe vice president of Global Program Leadership in Neurology and Immunology at EMD Serono discussed the recent long-term phase 2 data on evobrutinib presented at CMSC 2020.Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MSHead of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.Natalizumab Sets Itself Apart From Other MS TreatmentsCarrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MSThe clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.Why Learning About Masculine Norms Can Improve MS CareIn Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.
After receiving Stem Cell Therapy with Dr. Wagner, Jamie says she is no longer in pain and it’s been a 100% change for her lifestyle and all the activities she back to doing!Mary was diagnosed with the stage 3 osteoarthritis in her hip and was told it may be time for hip replacement. Copyright © 2020 Seattle Sports & Regenerative Medicine | All Rights Reserved | With outstanding results, Dr. Mark Wagner, M.D.